WaveMan
WaveMan · SEC 13F
Empery Asset Management, LP 13F holdings
> Search tickers & screens ⌘K
LIVE

Empery Asset Management, LP 13F holdings

Empery Asset Management, LP reported 32 positions with a total reported value of $86.5M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-11. Top holdings by reported value: XFOR X4 PHARMACEUTICALS INC (37.4%), EMPD EMPERY DIGITAL INC (12.1%), NGEN NERVGEN PHARMA CORP (9.5%), DTIL PRECISION BIOSCIENCES INC (7.1%), CLNN CLENE INC (6.5%). Against 2026-03-31 it opened 11 new positions and exited 10. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.

Email me when Empery Asset Management, LP files its 13F

A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.

Top holdings

25 largest of 32 positions · reported value as of 2026-06-30
HoldingSharesReported value% of portfolio
XFOR X4 PHARMACEUTICALS INC6,930,591$32.4M37.4%
EMPD EMPERY DIGITAL INC2,930,345$10.4M12.1%
NGEN NERVGEN PHARMA CORP4,000,000$8.2M9.5%
DTIL PRECISION BIOSCIENCES INC776,093$6.1M7.1%
CLNN CLENE INC916,532$5.6M6.5%
ANVS ANNOVIS BIO INC2,401,476$4.5M5.2%
LTRN LANTERN PHARMA INC842,669$3.5M4.1%
AMC ENTMT HLDGS INC1,714,043$3.3M3.8%
TNYA TENAYA THERAPEUTICS INC3,863,115$2.9M3.3%
ONE AND ONE GREEN TECHNOLOGI761,706$1.5M1.8%
CYN CYNGN INC927,059$1.3M1.5%
VENU VENU HLDG CORP512,818$1.2M1.3%
GLND GREENLAND ENERGY CO1,000,000$850.0K1.0%
URG UR-ENERGY INC620,136$843.4K1.0%
MSLE SATELLOS BIOSCIENCE INC107,100$832.7K1.0%
JAGU JAGUAR URANIUM CORP487,500$814.1K0.9%
CLRB CELLECTAR BIOSCIENCES INC189,605$527.1K0.6%
SCYX SCYNEXIS INC126,451$514.7K0.6%
RNTX REIN THERAPEUTICS INC370,834$385.7K0.4%
BTCT BTC DIGITAL LTD350,877$288.9K0.3%
BCTX BRIACELL THERAPEUTICS CORP300,000$267.0K0.3%
MTEK MARIS TECH LTD297,600$58.0K<0.1%
PRZO PARAZERO TECHNOLOGIES LTD113,771$55.3K<0.1%
DUKR DUKE ROBOTICS CORP35,000$45.1K<0.1%
NTRB NUTRIBAND INC40,218$40.2K<0.1%
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES

New positions this quarter

Held at 2026-06-30, not at 2026-03-31 · 11 in all · reported value as of 2026-06-30
HoldingSharesReported value% of portfolio
NGEN NERVGEN PHARMA CORP4,000,000$8.2M9.5%
CLNN CLENE INC916,532$5.6M6.5%
ANVS ANNOVIS BIO INC2,401,476$4.5M5.2%
LTRN LANTERN PHARMA INC842,669$3.5M4.1%
AMC ENTMT HLDGS INC1,714,043$3.3M3.8%
ONE AND ONE GREEN TECHNOLOGI761,706$1.5M1.8%
GLND GREENLAND ENERGY CO1,000,000$850.0K1.0%
CLRB CELLECTAR BIOSCIENCES INC189,605$527.1K0.6%
RNTX REIN THERAPEUTICS INC370,834$385.7K0.4%
BTCT BTC DIGITAL LTD350,877$288.9K0.3%
DUKR DUKE ROBOTICS CORP35,000$45.1K<0.1%

Sold out

Held at 2026-03-31, gone by 2026-06-30 · 10 in all · reported value as of 2026-03-31
HoldingShares 2026-03-31Reported value% of portfolio then
IMPERIAL PETE INC877,645$3.8M4.5%
U S ENERGY CORP DEL1,917,844$1.7M2.0%
CRML CRITICAL METALS CORP132,039$1.0M1.3%
PMN PROMIS NEUROSCIENCES INC60,353$766.5K0.9%
SLE SUPER LEAGUE ENTERPRISE INC132,917$491.8K0.6%
TLPH TALPHERA INC590,481$441.0K0.5%
BNTC BENITEC BIOPHARMA INC30,440$324.2K0.4%
ABTS ABITS GROUP INC172,761$266.1K0.3%
NSRX NASUS PHARMA LTD45,803$101.7K0.1%
MDCX MEDICUS PHARMA LTD12,100$11.5K<0.1%

Biggest increases and decreases

Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30

Increases

No position was increased.

Decreases

HoldingShares 2026-03-31Shares 2026-06-30ChangeReported value
XFOR X4 PHARMACEUTICALS INC8,944,1186,930,591-22.5%$32.4M
DTIL PRECISION BIOSCIENCES INC1,968,879776,093-60.6%$6.1M
SCYX SCYNEXIS INC1,847,826126,451-93.2%$514.7K
VENU VENU HLDG CORP1,007,729512,818-49.1%$1.2M
MSLE SATELLOS BIOSCIENCE INC230,100107,100-53.5%$832.7K
BCTX BRIACELL THERAPEUTICS CORP966,600300,000-69.0%$267.0K
TNYA TENAYA THERAPEUTICS INC4,286,9333,863,115-9.9%$2.9M
PRZO PARAZERO TECHNOLOGIES LTD282,199113,771-59.7%$55.3K
CYN CYNGN INC957,784927,059-3.2%$1.3M
CIK 1469336 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-27 · For informational purposes only, not investment advice.
Privacy · Terms